Publications by authors named "Isabel Castrejon"

Claim this Profile
I
Improving early referrals for inflammatory arthritis through primary care engagement: a quality improvement initiative.
Camille Bourgeois, Marina Sánchez-Lucas, Jorge Olmedo-Galindo, María Teresa Schiaffino, Tamara Del Río, Isabel Castrejon

Rheumatol Adv Pract· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis in Spain and Barriers to Implementation: A Delphi Study.
Esteban Rubio, Mª José Moreno, Adela Gallego, Isabel Castrejón, Amelia Cobo

Adv Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registry.
Juan Molina-Collada, Lucía Otero-Varela, Paloma Vela, Sara Manrique, Celia Erausquin

Rheumatology (Oxford)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study.
Stylianos Georgiadis, Daniela Di Giuseppe, Almut Scherer, Merete Lund Hetland, Gareth T Jones, Isabel Castrejon

BMC Rheumatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network.
Marion Pons, Stylianos Georgiadis, Merete Lund Hetland, Zohra Faizy Ahmadzay, Simon Rasmussen

J Rheumatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in patients with rheumatological diseases.
Maria Giulia Caponcello, Paula Olivares Navarro, Cecilia Bonazzetti, Caterina Campoli, Alessia Savoldi

Clin Microbiol Infect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.
Brigitte Michelsen, Mikkel Østergaard, Michael John Nissen, Adrian Ciurea, Burkhard Möller

Health Policy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis.
Marion Pons, Stylianos Georgiadis, Mikkel Østergaard, Zohra Faizy Ahmadzay, Bente Glintborg

Joint Bone Spine· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry.
Paloma Vela-Casasempere, Lucía Otero-Varela, Silvia Gómez Sabater, Rocío Caño Alameda, Cristina Campos Fernández

Arthritis Res Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry.
Clementina López-Medina, Lucía Otero-Varela, Fernando Sánchez-Alonso, Vega Jovaní, Lorena Expósito-Pérez

Reumatol Clin (Engl Ed)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
Pasoon Hellamand, Marleen G H van de Sande, Michael T Nurmohamed, Ronald F van Vollenhoven, Rosemary J Hollick, Isabel Castrejon

Rheumatology (Oxford)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different giant cell arteritis phenotypes may present distinct types of ischaemic complications.
Helena M Amar Muñoz, Juan Molina-Collada, Isabel Castrejón, Irene Monjo-Henry, Elisa Fernández-Fernández

Clin Exp Rheumatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries.
Adrian Ciurea, Seraphina Kissling, Andrea Götschi, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, Isabel Castrejon

Arthritis Res Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries.
Louise Linde, Stylianos Georgiadis, Lykke M Ørnbjerg, Simon H Rasmussen, Brigitte Michelsen, Isabel Castrejon

Arthritis Care Res (Hoboken)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey.
Zohra F Ahmadzay, Jette Heberg, Jacob B Jørgensen, Lykke M Ørnbjerg, Mikkel Østergaard, Isabel Castrejon

Rheumatol Adv Pract· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interrater reliability of RheuMetric checklist scales for physician global assessment, inflammation, damage and patient distress.
Juan Schmukler, Isabel Castrejon, Tengfei Li, Joel A Block, Theodore Pincus

Rheumatol Adv Pract· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care.
Isabel Castrejón, Laura Cano, María José Cuadrado, Joaquín Borrás, Maria Galindo

BMC Rheumatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry.
María Paz Martínez-Vidal, Cristina Fernández-Carballido, Lucía Otero-Varela, Francisco Javier Manero Ruiz, Yanira Pérez-Vera

J Rheumatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
Blanca Hernández-Cruz, Lucía Otero-Varela, Mercedes Freire-González, Noemí Busquets-Pérez, Alfredo Javier García González

Ann Rheum Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care.
Isabel Castrejón, Laura Cano, María José Cuadrado, Joaquín Borrás, Maria Galindo

BMC Rheumatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
Sara Nysom Christiansen, Simon Horskjær Rasmussen, Mikkel Ostergaard, Marion Pons, Brigitte Michelsen, Isabel Castrejon

RMD Open· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early identification of golimumab-treated patients with higher likelihood of long-term retention.
Alicia García-Dorta, Enrique González-Dávila, Marta Sánchez-Jareño, Luis Cea-Calvo, Manuel Pombo-Suárez

Front Immunol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage re-programming by JAK inhibitors relies on MAFB.
Baltasar López-Navarro, Miriam Simón-Fuentes, Israel Ríos, María Teresa Schiaffino, Alicia Sanchez

Cell Mol Life Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center.
Javier Rivera, Juan Molina-Collada, Julia Martínez-Barrio, Belén Serrano-Benavente, Isabel Castrejón

BMC Musculoskelet Disord· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry.
Jerusalem Calvo-Gutiérrez, Clementina López-Medina, Lucía Otero-Varela, Alejandro Escudero-Contreras, Rafaela Ortega-Castro

Arthritis Res Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis